|
Acambis Public Limited Company, founded in 1992 and based in Cambridge, England, is a biotechnology firm that develops infectious disease treatments. The company is known for its proprietary ChimeriVax (TM) technologies, developed in alliance with St. Louis University, Sanofi Pasteur, and Bharat Biotech. ChimeriVax-JE is a Japanese encephalitis virus vaccine. ChimeriVax-West Nile is a West Nile virus vaccine. ChimeriVax-Dengue prevents dengue fever. The company has developed the world's only Clostridium difficile bacteria vaccine. Acambis' ACAM-FLU-A (TM), in clinical trials, is a universal vaccine against influenza. The company's ACAM2000 (TM), licensed by the United States Food and Drug Administration (FDA) in 2007, is a smallpox vaccine. The U.S. government has stockpiled the ACAM2000 for emergency use. Acambis maintains additional offices in Cambridge, Massachusetts and Rockville, Maryland. The firm was founded as Peptide Therapeutics in 1992. It acquired its current name in 2000. Acambis was listed on NASDAQ in 2001. It de-listed in 2006. Currently, the company is listed on the London Stock Exchange under the ACM symbol.
|
Information Sources, Inc.